KKCG
Kapellgasse 21, Lucerne, Luzern, 6004, Switzerland
Overview
KKCG is an investment and innovation group with expertise in lotteries and gaming, energy, technology, and real estate. Founded by entrepreneur, investor, and philanthropist Karel Komárek, KKCG employs over 16,000 people in 37 countries across its portfolio companies, with more than €10 billion in assets under management. KKCG’s businesses include, amongst others, Allwyn, a multi-national lottery operator; MND Group, an international producer and supplier of traditional and renewable energy; ARICOMA, Avenga and Qinshift, providing comprehensive IT services and custom software development around the globe; and KKCG Real Estate Group. With operations on several continents, KKCG businesses draw on capital, networks, and insights from across the group to enable profitable, sustainable growth for the long term. KKCG is committed to supporting the communities where it operates, contributing to the societies it works within.
- Total investments
- 3
- Lead investments
- 1
- Investments · 12mo
- 1
- Active investors
- 2
Investment portfolio
- Zilch
Led · Equity · Nov 2025
Founded in 2020, Zilch provides a BNPL card that allows users to pay via debit or credit and settle balances in interest-free instalments, with merchant advertising subsidies offsetting consumer costs. The company competes with Klarna and Clearpay in the UK consumer lending market. Zilch reports a customer base of more than 5 million and has previously been valued at roughly £1.5 billion. Its platform combines payments and marketing, giving merchants a channel to reach customers while offering shoppers flexible credit. The firm’s near-term priorities include ramping up marketing campaigns, advancing product development, and pursuing strategic acquisitions. Investors such as Goldman Sachs and eBay have backed the company in earlier rounds. Management claims the latest funding reinforces confidence in its strategy and ability to scale rapidly.
- Mahana Therapeutics
Participated · Series B · Aug 2021
Mahana Therapeutics is a San Francisco–based developer of prescription digital therapeutics that deliver cognitive behavioral therapy (CBT) for chronic conditions. Its lead product, Mahana IBS, is an FDA‑cleared, prescription‑only digital therapeutic delivered via web and mobile apps and indicated as a three‑month CBT treatment for adults with IBS. Mahana IBS showed effectiveness in a 558‑patient clinical trial, with patients experiencing significant improvements in IBS symptom severity and daily functioning. The company plans to use new capital to launch Mahana IBS commercially and to accelerate development of several additional digital therapeutics for chronic health conditions. The app is available for iOS and Android and may be used alongside other IBS treatments. Mahana emphasizes expanding patient access to CBT where licensed clinicians are scarce.
- Freeletics
Participated · Series B · Sep 2020
Freeletics provides AI-powered fitness and mindset coaching via a mobile app that generates personalized training plans and workouts. Its algorithms learn from millions of users and individual feedback to create adaptive, context-aware training journeys, with the coach able to draw from 3.5 million workout options. The product pairs hyper-personalized physical training with audio-based mindset coaching aimed at building sustainable habits and long-term behavior change. The company operates a freemium model with paid subscriptions that bundle training, nutrition, and mindset features. Freeletics reports 48 million users in over 160 countries and more than 600,000 paid subscriptions, having doubled its paying subscriber base over the last year. The company plans to use new capital to develop technology, expand globally (with continued U.S. growth efforts), and launch new business verticals. Freeletics operates a freemium mobile fitness coaching app that delivers AI-powered, personalized training plans and fitness content. The app offers tiered paid plans (from $11.99/month or $74.99/year) and plans to add a Netflix-style training platform and nutritional guidance for paying users. It intentionally does not plan to expand into hardware. Freeletics says it has 31 million users across more than 160 countries and has seen 120% U.S. user growth in the past six months. Headquartered in Munich, the company has focused on scaling internationally after initially concentrating on Germany. Freeletics aims to help users adopt long-term athletic lifestyles through tech-driven, adaptive coaching at scale.